

Aleksandar Stojmirović, PhD

North Wales, PA • aleksandar04@stojmirovic.org • 301-331-8371

<https://www.linkedin.com/in/aleksandar-stojmirovic-92064946>

Director-level translational data science leader building scientific products and evidence platforms that improve R&D decisions across target selection, biomarker strategy, MoA confidence, and objective endpoints. Led vertically integrated teams spanning translational analysis, data products, and platform engineering; bench-credible scientist turned platform builder across therapeutic areas and modalities.

SELECTED IMPACT

- **Scientific products adopted across R&D.** Shaped direction, standards, and platform foundations; my team delivered 12+ integrated single-cell atlases now used in Immunology, Oncology, and Neuroscience for target characterization, biomarker strategy, and MoA assessment.
- **AI-ready evidence data foundation.** Built a scalable single-cell and bulk analysis-ready foundation on TileDB-SOMA with internal extensions; powers hundreds of datasets and enables self-serve visualization of human molecular and clinical-study-linked transcriptomic data, saving more than \$100K/month.
- **Governed translational data at enterprise scale.** Led end-to-end translational data management capabilities across R&D covering 4,000+ experiments, 19M files, and 2.2 PB, with FAIR metadata, lineage, and QC.
- **Objective endpoints from multimodal biology.** Co-led (with clinician partner) a GI computer-vision strategy spanning digital histopathology and endoscopy — external partnerships, data/labeling standards, fitness-for-use criteria, and technical due diligence.
- **Mechanism-to-portfolio decisions.** Partnered with a biologist to develop a mechanistic rationale for combination therapy, later supported in Phase 2a and advanced into later development; co-led target prioritization for novel IBD therapeutics.
- **Scientific credibility + executive communication.** ~35 publications (full list available upon request); translate multimodal evidence into crisp program and portfolio recommendations. Five Innovation Leadership Awards, including 2021 enterprise-wide Spark Innovation Award.

EXPERIENCE

5/2026 – Present | Founder / Principal Consultant, Stoyalex Consulting LLC

- Advise scientific-software companies on pharma product strategy, translating R&D workflows and customer needs into reusable capabilities and AI-ready data foundations; expanding into translational evidence strategy, ontology harmonization, and external data/AI diligence.

9/2021 – 5/2026 | Director, Data Science → Distinguished Data Scientist (Director level), R&D Data Science & Digital Health, Johnson & Johnson Innovative Medicine

- Led Data Strategy & Products interface for Immunology/Cardiopulmonary; aligned TA priorities to enterprise strategy, supported GenAI data readiness, and acted as Immunology-facing product lead for data hubs and visualization/access products.
- Previously led Translational Data Engineering & Solutions, delivering governed end-to-end translational data capabilities across R&D and guiding platform/data engineering priorities

for high-dimensional single-cell and bulk molecular datasets.

- Served as business/product lead for R&D-facing scientific data applications and platforms, guiding roadmaps, prioritization, user adoption, compliance-aligned requirements, and self-service access patterns.
- Shaped enterprise single-cell atlas strategy, standards, and platform foundations, enabling reusable atlas products across therapeutic areas.
- Co-led AI-enabled objective endpoint strategy in gastroenterology with a clinician partner and directed external partnerships spanning digital histopathology and endoscopy algorithms.

10/2019 – 9/2021 | Associate Scientific Director, Immunology Data Science → R&D Data Science, Janssen Research & Development (Johnson & Johnson)

7/2013 – 9/2019 | Scientist → Senior Scientist → Principal Scientist, Immunology Therapeutic Area, Janssen Research & Development (Johnson & Johnson)

- Generated decision-grade mechanistic evidence in inflammatory and autoimmune diseases, linking multimodal molecular data to MoA and biomarker hypotheses used in program strategy and portfolio discussions.
- Co-led an interdisciplinary target-prioritization effort for novel IBD therapeutics, integrating computational evidence with biology to advance and de-risk target choices.
- Built and product-led a network-based evidence platform spanning network storage, enrichment, and biologist-facing visualization, incorporating original methods and algorithms; applied it with a biologist to develop a human disease-network rationale for combination therapy later supported in Phase 2a.
- Established an operating model for omics/biomarker data management: defined best practices, led migration to centrally organized annotated datasets, and recruited/organized the team to implement and sustain the solution.
- Developed a metadata-capture solution embedded in translational ingestion workflows to preserve experimental and analytical context for downstream reuse and reproducibility.
- Led and contributed to external scientific collaborations with academic KOLs and pre-competitive consortia, producing publications and aligning data-sharing standards and requirements that supported internal discovery and translational efforts.

8/2006 – 7/2013 | Visiting Fellow → Research Fellow, National Center for Biotechnology Information (NCBI), National Institutes of Health

- Developed algorithms and tools for biological network analysis and protein sequence analysis.

7/2005 – 7/2006 | Postdoctoral Fellow, Department of Mathematics and Statistics, University of Ottawa, Canada

EDUCATION

Victoria University of Wellington, New Zealand

PhD, Mathematics, 2005

BSc (Hons, First Class), Mathematics, 1999

BSc, Biochemistry & Molecular Biology; Genetics & Molecular Biology; Mathematics, 1998